Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Methodol. Mar 20, 2026; 16(1): 107864
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.107864

Table 3 Quality assessment for observational/cross-sectional studies (Newcastle-Ottawa scale)

Citation: Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fatima FB, Kumar D, Rizvi SAFA, Jabeen S, Jawed I, Qadir U, Zakeri MA. Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. World J Methodol 2026; 16(1): 107864
URL: https://www.wjgnet.com/2222-0682/full/v16/i1/107864.htm
DOI: https://dx.doi.org/10.5662/wjm.v16.i1.107864

Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fatima FB, Kumar D, Rizvi SAFA, Jabeen S, Jawed I, Qadir U, Zakeri MA. Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. World J Methodol 2026; 16(1): 107864 [PMID: 41809182 DOI: 10.5662/wjm.v16.i1.107864]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.